People · Operator
Named in public records as an officer, director or promoter · active 2017–2025 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Alumis Inc. | — | Biotechnology | Series D+ | $240.0M | $432.7M | 2024 |
| Harpoon Therapeutics, Inc. | — | Biotechnology | Series D+ | $220.3M | $1.4B | 2023 |
| VelosBio Inc. | — | Biotechnology | Series D+ | $210.5M | $5.6B | 2018 |
| Solve Therapeutics, Inc. | — | Biotechnology | Series C | $162.1M | $254.7M | 2021 |
| Principia Biopharma Inc. | — | Biotechnology | Series C | $77.4M | $2.0B | 2018 |
| InCarda Therapeutics, Inc. | — | Pharmaceuticals | Series B | $66.3M | $856.6M | 2017 |
| Anumana, Inc. | — | Biotechnology | Series B | $32.0M | $464.2M | 2022 |
Alan Colowick at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Alan Colowick on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Johnson | 2 | 35 |
| Srinivas Akkaraju | 2 | 10 |
| Mark Chin | 2 | 4 |
| MARTIN BABLER | 2 | 2 |
| Langdon Miller | 2 | 2 |
| Peter Thompson | 1 | 16 |
| Isaac Cheng | 1 | 9 |
| Scott L. Glenn | 1 | 9 |
| Simeon George | 1 | 8 |
| Cam Gallagher | 1 | 7 |
| Richard Gaster | 1 | 7 |
| Andrew ElBardissi | 1 | 7 |
| James Tananbaum | 1 | 6 |
| MICHAEL DYBBS | 1 | 5 |
| MIN CUI | 1 | 5 |
| Daniel Becker | 1 | 5 |
| Peter Colabuono | 1 | 4 |
| Lewis J. Shuster | 1 | 4 |
| Nassim Usman | 1 | 4 |
| Harris Fishman | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.